Tatsuno, Saori
Doi, Hiroshi http://orcid.org/0000-0003-3237-2119
Inada, Masahiro
Uehara, Takuya
Wada, Yutaro
Ishikawa, Kazuki
Tanaka, Kaoru
Kitano, Mutsukazu
Nishimura, Yasumasa
Funding for this research was provided by:
Japan Society for the Promotion of Science London (JP22K07733, JP20K08009)
Article History
Received: 2 May 2023
Accepted: 10 September 2023
First Online: 24 November 2023
Declarations
:
: K. Tanaka reports personal fees from AstraZeneca, Merck Serono, Ono Pharmaceutical, Bristol Myers Squibb, Eisai, and MSD outside the submitted work. S. Tatsuno, H. Doi, M. Inada, T. Uehara, Y. Wada, K. Ishikawa, M. Kitano and Y. Nishimura declare that they have no competing interests.
: This study was conducted in accordance with the guidelines of the Declaration of Helsinki. This study was approved by our institutional review board (approval number R02-112). Written informed consent for radiotherapy was obtained from all individual participants prior to radiotherapy. Informed consent for this study was obtained in the form of opt-out.